Stage (next event)
Phase 3 TBA
Catalyst Info & Data Links
TITLE: Oral Korsuva in Pruritus CKD 3-5
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
Phase 2 Topline Results - Oral KORSUVATM for CKD-associated Pruritus
05-2020: Corporate Presentation (slide 29)
Mechanism of Action
MECHANISM OF ACTION / RATIONALE
Difelikefalin (CR845) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons and immune cells. The hydrophilic small-peptide structure restricts passive diffusion across membranes, thereby limiting access to kappa opioid receptors in the central nervous system (Fishbane et al., 2020).
~7.3 million diagnosed with CKD (IQVIA est)
source - slide 3
Updated by MV
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post